TScan Therapeutics (TCRX) Cash from Financing Activities (2020 - 2025)

TScan Therapeutics (TCRX) has 6 years of Cash from Financing Activities data on file, last reported at $73000.0 in Q4 2025.

• On a quarterly basis, Cash from Financing Activities fell 99.84% year-over-year to $73000.0 in Q4 2025; TTM through Dec 2025 was -$336000.0, a 100.16% decrease from a year earlier, with the FY2025 full-year figure at -$336000.0, down 100.16% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $73000.0, down from $116000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for TCRX reached as high as $161.6 million in Q2 2024 and fell as low as -$686000.0 in Q2 2021.
• Historically, Cash from Financing Activities has averaged $25.1 million across 5 years, with a median of $116000.0 in 2025.
• Across the five-year window, Cash from Financing Activities jumped 9060700.0% in 2021 and sank 303.49% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $120000.0 in 2021, then retreated by 10.0% to $108000.0 in 2022, then tumbled by 82.41% to $19000.0 in 2023, then surged by 240373.68% to $45.7 million in 2024, then sank by 99.84% to $73000.0 in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $73000.0 in Q4 2025, $116000.0 in Q2 2025, and -$525000.0 in Q1 2025.